RonaldLShazerMD

Clinical Trials

• Single-dose Safety Study of APD916 in Healthy Volunteers Start of enrollment: 2010 Mar 01

  Completed

  Phase 1

• Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study Start of enrollment: 2021 Jun 30

  Active, not recruiting

  Phase 2, Phase 3

• Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors Start of enrollment: 2008 Jun 01

  Withdrawn

  Phase 1

• Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion Start of enrollment: 2022 Jun 02

  Recruiting

  Phase 1, Phase 2

• Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2019 Jul 15

  Active, not recruiting

  Phase 3

• Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Start of enrollment: 2016 Nov 07

  Terminated

  Phase 2

• Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Start of enrollment: 2022 Aug 01

  Recruiting

  Phase 1, Phase 2

• Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) Start of enrollment: 2022 Feb 01

  Active, not recruiting

  Phase 1

• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) Start of enrollment: 2021 Aug 12

  Completed

  Phase 1

• Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Start of enrollment: 2020 Apr 22

  Active, not recruiting

  Phase 1, Phase 2

• Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Start of enrollment: 2024 Jan 30

  Recruiting

  Phase 1

• Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients Start of enrollment: 2016 Sep 21

  Completed

  Phase 2

• Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2015 Apr 14

  Active, not recruiting

  Phase 2

• Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer Start of enrollment: 2003 Mar 01

  Completed

  Phase 2

• Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) Start of enrollment: 2006 May 01

  Completed

  Phase 2

• Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors Start of enrollment: 2003 Nov 01

  Completed

  Phase 1

• Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2005 Apr 01

  Completed

  Phase 3

• Join now to see all